# CDK5 interacts with MST2 and modulates the Hippo signalling pathway

**Authors:** Mehak Passi, Jan B. Stöckl, Thomas Fröhlich, Simone Moser, Angelika M. Vollmar, Stefan Zahler

PMC · DOI: 10.1002/2211-5463.13962 · FEBS Open Bio · 2024-12-30

## TL;DR

CDK5 interacts with MST2 and affects the Hippo signaling pathway, which is important for controlling cell growth and tissue development.

## Contribution

The study identifies a novel interaction between CDK5 and MST2 that modulates the Hippo signaling pathway.

## Key findings

- CDK5 knockdown reduces YAP transcriptional activity.
- CDK5 influences phosphorylation levels of LATS1 and DLG5.
- CDK5 acts as a signaling hub integrating Hippo with other pathways.

## Abstract

MST2 (STK3) is a major upstream kinase in the Hippo signalling pathway, an evolutionary conserved pathway in regulation of organ size, self‐renewal and tissue homeostasis. Its downstream effectors are the transcriptional regulators YAP and TAZ. This pathway is regulated by a variety of factors, such as substrate stiffness or cell–cell contacts. Using a yeast two‐hybrid screen, we detected a novel interaction between the kinases MST2 and CDK5, which we further confirmed by co‐immunoprecipitation experiments. Cyclin‐dependent kinase 5 (CDK5) is an unusual member of the family of cyclin‐dependent kinases, involved in tumour growth and angiogenesis. Although a link between CDK5 and Hippo has been previously postulated, the mode of action is still elusive. Here, we show that knockdown of CDK5 causes reduced transcriptional activity of YAP and that CDK5 influences the phosphorylation levels of the Hippo upstream kinase LATS1. Moreover, a phosphoproteomics approach revealed that CDK5 interferes with the phosphorylation of DLG5, another upstream kinase, which regulates the Hippo pathway. Hence, CDK5 seems to act as a signalling hub for integrating the Hippo pathway and other signalling cascades. These interactions might have important implications for the use of CDK5 inhibitors, which are already in clinical use for tumour diseases.

By using a yeast‐two‐hybrid system, immune precipitation and a proteomics approach, we identify a novel interaction between CDK5 and MST2, which modulates the mechano‐sensitive Hippo signalling pathway in a liver tumour cell line.

## Linked entities

- **Genes:** STK3 (serine/threonine kinase 3) [NCBI Gene 6788], STK3 (serine/threonine kinase 3) [NCBI Gene 6788], CDK5 (cyclin dependent kinase 5) [NCBI Gene 1020], YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413], TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901], LATS1 (large tumor suppressor kinase 1) [NCBI Gene 9113], DLG5 (discs large MAGUK scaffold protein 5) [NCBI Gene 9231]

## Full-text entities

- **Genes:** DLG5 (discs large MAGUK scaffold protein 5) [NCBI Gene 9231] {aka LP-DLG, P-DLG5, PDLG, YUVOB}, STK3 (serine/threonine kinase 3) [NCBI Gene 6788] {aka KRS1, MST2}, LATS1 (large tumor suppressor kinase 1) [NCBI Gene 9113] {aka WARTS, wts}, TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901] {aka BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, CDK5 (cyclin dependent kinase 5) [NCBI Gene 1020] {aka LIS7, PSSALRE}
- **Diseases:** tumour (MESH:D009369)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11961382/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11961382/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC11961382/full.md

---
Source: https://tomesphere.com/paper/PMC11961382